Subscribe to eNews Contact us / IVR

Use of urine-based biomarkers in patients with microhematuria bibliography

  1. Banek S, Schwentner C, Tager D, et al. Prospective evaluation of fluorescence-in situ-hybridization to detect bladder cancer: results from the UroScreen-Study. Urol Oncol. Nov 2013;31(8):1656-62. doi:10.1016/j.urolonc.2012.04.015
  2. Barocas D, Lotan Y, Matulewicz R, et al. Microhematuria: AUA/SUFU Guideline. J Urol. 2025;213(5):547-557. doi:10.1097/JU.0000000000004490
  3. Budman L, Kassouf W, Steinberg J. Biomarkers for detection and surveillance of bladder cancer. Can Urol Assoc J. 2008;2(3):212-221. doi:10.5489/cuaj.600
  4. Cha EK, Tirsar LA, Schwentner C, et al. Immunocytology is a strong predictor of bladder cancer presence in patients with painless hematuria: a multicentre study. Eur Urol. Jan 2012;61(1):185-92. doi:10.1016/j.eururo.2011.08.073
  5. Cha EK, Tirsar LA, Schwentner C, et al. Accurate risk assessment of patients with asymptomatic hematuria for the presence of bladder cancer. World J Urol. Dec 2012;30(6):847-52. doi:10.1007/s00345-012-0979-x
  6. Chiong E, Gaston KE, Grossman HB. Urinary markers in screening patients with hematuria. World J Urol. Feb 2008;26(1):25-30. doi:10.1007/s00345-007-0229-9
  7. Dal Moro F, Valotto C, Guttilla A, Zattoni F. Urinary markers in the everyday diagnosis of bladder cancer. Urologia. Sep-Dec 2013;80(4):265-75. doi:10.5301/urologia.5000041
  8. Davidson P, McGeoch G, Shand B. Assessment of a clinical pathway for investigation of haematuria that reduces the need for cystoscopy. N Z Med J. 2020;133(1527):71-82.
  9. Denice Smith G, Sangle NA, Wilson A, et al. A retrospective review of UroVysion fish interpretations over 8.6 years: a major shift in the patient test population. Diagn Cytopathol. May 2013;41(5):437-47. doi:10.1002/dc.22881
  10. Dudderidge T, Stockley J, Nabi G, et al. A Novel, non-invasive Test Enabling Bladder Cancer Detection in Urine Sediment of Patients Presenting with Haematuria-A Prospective Multicentre Performance Evaluation of ADXBLADDER. Eur Urol Oncol. Feb 2020;3(1):42-46. doi:10.1016/j.euo.2019.06.006
  11. Gopalakrishna A, Longo TA, Fantony JJ, et al. The diagnostic accuracy of urine-based tests for bladder cancer varies greatly by patient. BMC Urol. Jun 13 2016;16(1):30. doi:10.1186/s12894-016-0147-5
  12. Grossman H, Messing E, Soloway M, et al. Detection of bladder cancer using a point-of-care proteomic assay. JAMA. 2005;293(7):810-816. doi:10.1001/jama.293.7.810
  13. Harvey JC, Fletcher D, Ellen CW, et al. Analytical Validation of the Cxbladder((R)) Triage Plus Assay for Risk Stratification of Hematuria Patients for Urothelial Carcinoma. Diagnostics (Basel). Jul 8 2025;15(14)doi:10.3390/diagnostics15141739
  14. Hayashi Y, Fujita K, Matsuzaki K, et al. Clinical Significance of Hotspot Mutation Analysis of Urinary Cell-Free DNA in Urothelial Bladder Cancer. Front Oncol. 2020;10:755. doi:10.3389/fonc.2020.00755
  15. Heard JR, Mitra AP. Noninvasive Tests for Bladder Cancer Detection and Surveillance: A Systematic Review of Commercially Available Assays. Bladder Cancer. 2024;10(1):71-81. doi:10.3233/BLC-230096
  16. Ho CC, Tan WP, Pathmanathan R, Tan WK, Tan HM. Fluorescence-in-situ-hybridization in the surveillance of urothelial cancers: can use of cystoscopy or ureteroscopy be deferred? Asian Pac J Cancer Prev. 2013;14(7):4057-9. doi:10.7314/apjcp.2013.14.7.4057
  17. Hwang EC, Choi HS, Jung SI, Kwon DD, Park K, Ryu SB. Use of the NMP22 BladderChek test in the diagnosis and follow-up of urothelial cancer: a cross-sectional study. Urology. Jan 2011;77(1):154-9. doi:10.1016/j.urology.2010.04.059
  18. Kavcic N, Peric I, Zagorac A, Kokalj Vokac N. Clinical Evaluation of Two Non-Invasive Genetic Tests for Detection and Monitoring of Urothelial Carcinoma: Validation of UroVysion and Xpert Bladder Cancer Detection Test. Front Genet. 2022;13:839598. doi:10.3389/fgene.2022.839598
  19. Ke C, Liu X, Wan J, Hu Z, Yang C. UroVysion() fluorescence in situ hybridization (FISH) possibly has a high positive rate in carcinoma of non-urothelial lineages. Front Mol Biosci. 2023;10:1250442. doi:10.3389/fmolb.2023.1250442
  20. Kuckuck EC, Hennenlotter J, Todenhofer T, et al. Discriminative capacity of guideline recommendations in the assessment of patients with asymptomatic microhematuria. Urol Oncol. May 2023;41(5):254 e1-254 e8. doi:10.1016/j.urolonc.2022.08.011
  21. Lotan Y, Daneshmand S, Shore N, et al. A Multicenter Prospective Randomized Controlled Trial Comparing Cxbladder Triage to Cystoscopy in Patients With Microhematuria: The Safe Testing of Risk for Asymptomatic Microhematuria Trial. J Urol. Jul 2024;212(1):41-51. doi:10.1097/JU.0000000000003991
  22. Lotan Y, Raman JD, Konety B, et al. Urinary Analysis of FGFR3 and TERT Gene Mutations Enhances Performance of Cxbladder Tests and Improves Patient Risk Stratification. J Urol. Apr 2023;209(4):762-772. doi:10.1097/JU.0000000000003126
  23. Lough T, Luo Q, Luxmanan C, et al. Clinical utility of a non-invasive urine test for risk assessing patients with no obvious benign cause of hematuria: a physician-patient real world data analysis. BMC Urol. Mar 9 2018;18(1):18. doi:10.1186/s12894-018-0327-6
  24. Magee D, Tharakan N, Yuiminaga Y. Validation of Cxbladder((R)) Triage and Monitor as an Adjunct to Urothelial Carcinoma Diagnosis and Surveillance in a Single Centre. Res Rep Urol. 2025;17:87-94. doi:10.2147/RRU.S516994
  25. Matulewicz RS, Rademaker A, Meeks JJ. A simplified nomogram to assess risk of bladder cancer in patients with a new diagnosis of microscopic hematuria. Urol Oncol. Apr 2020;38(4):240-246. doi:10.1016/j.urolonc.2019.12.010
  26. Nagai T, Naiki T, Etani T, et al. UroVysion fluorescence in situ hybridization in urothelial carcinoma: a narrative review and future perspectives. Transl Androl Urol. Apr 2021;10(4):1908-1917. doi:10.21037/tau-20-1207
  27. Network NCC. Bladder Cancer. 2025.
  28. O'Sullivan P, Sharples K, Dalphin M, et al. A multigene urine test for the detection and stratification of bladder cancer in patients presenting with hematuria. J Urol. Sep 2012;188(3):741-7. doi:10.1016/j.juro.2012.05.003
  29. Pijpers OM, de Jong JJ, Zuiverloon TCM, Boormans JL. RNA-based urinary assays for non-muscle invasive bladder cancer. Curr Opin Urol. Sep 1 2022;32(5):523-530. doi:10.1097/MOU.0000000000001018
  30. Raman JD, Kavalieris L, Konety B, et al. The Diagnostic Performance of Cxbladder Resolve, Alone and in Combination with Other Cxbladder Tests, in the Identification and Priority Evaluation of Patients at Risk for Urothelial Carcinoma. J Urol. Dec 2021;206(6):1380-1389. doi:10.1097/JU.0000000000002135
  31. Ruan W, Chen X, Huang M, et al. A urine-based DNA methylation assay to facilitate early detection and risk stratification of bladder cancer. Clin Epigenetics. Apr 26 2021;13(1):91. doi:10.1186/s13148-021-01073-x
  32. Sathianathen NJ, Butaney M, Weight CJ, Kumar R, Konety BR. Urinary Biomarkers in the Evaluation of Primary Hematuria: A Systematic Review and Meta-Analysis. Bladder Cancer. Oct 29 2018;4(4):353-363. doi:10.3233/BLC-180179
  33. Schmitz-Drager C, Goebell PJ, Paxinos E, et al. Potential of an mRNA-Based Urine Assay (Xpert((R)) Bladder Cancer Detection(1)) in Hematuria Patients - Results from a Cohort Study. Bladder Cancer. 2024;10(1):25-33. doi:10.3233/BLC-230089
  34. Sciarra A, Di Lascio G, Del Giudice F, et al. Comparison of the clinical usefulness of different urinary tests for the initial detection of bladder cancer: a systematic review. Curr Urol. Mar 2021;15(1):22-32. doi:10.1097/CU9.0000000000000012
  35. Soorojebally Y, Neuzillet Y, Roumiguie M, et al. Urinary biomarkers for bladder cancer diagnosis and NMIBC follow-up: a systematic review. World J Urol. Feb 2023;41(2):345-359. doi:10.1007/s00345-022-04253-3
  36. Tan WS, Ahmad A, Feber A, et al. Development and validation of a haematuria cancer risk score to identify patients at risk of harbouring cancer. J Intern Med. Apr 2019;285(4):436-445. doi:10.1111/joim.12868
  37. Tan WS, Ahmad A, Zhou Y, et al. Hematuria Cancer Risk Score with Ultrasound Informs Cystoscopy Use in Patients with Hematuria. Eur Urol Oncol. Feb 2025;8(1):87-93. doi:10.1016/j.euo.2024.05.005
  38. Todenhofer T, Hennenlotter J, Kuhs U, et al. Influence of urinary tract instrumentation and inflammation on the performance of urine markers for the detection of bladder cancer. Urology. Mar 2012;79(3):620-4. doi:10.1016/j.urology.2011.10.067
  39. Todenhofer T, Hennenlotter J, Tews V, et al. Impact of different grades of microscopic hematuria on the performance of urine-based markers for the detection of urothelial carcinoma. Urol Oncol. Oct 2013;31(7):1148-54. doi:10.1016/j.urolonc.2011.10.011
  40. Turkeri L, Mangir N, Gunlusoy B, et al. Identification of patients with microscopic hematuria who are at greater risk for the presence of bladder tumors using a dedicated questionnaire and point of care urine test--a study by the members of Association of Urooncology, Turkey. Asian Pac J Cancer Prev. 2014;15(15):6283-6. doi:10.7314/apjcp.2014.15.15.6283
  41. van Kessel KE, Van Neste L, Lurkin I, Zwarthoff EC, Van Criekinge W. Evaluation of an Epigenetic Profile for the Detection of Bladder Cancer in Patients with Hematuria. J Urol. Mar 2016;195(3):601-7. doi:10.1016/j.juro.2015.08.085
  42. Zhou L, Yang K, Li X, et al. Application of fluorescence in situ hybridization in the detection of bladder transitional-cell carcinoma: A multi-center clinical study based on Chinese population. Asian J Urol. Jan 2019;6(1):114-121. doi:10.1016/j.ajur.2018.06.001